18 research outputs found
Headache of recent onset in adults: a prospective population-based study
One hundred consecutive adult patients with headache of recent onset were
prospectively studied. Every patient was examined by craneal CT scan. Their
mean age was 46 years (range 17-82). Neurological examination was normal
in 80 patients. Organic headache represented 39% of the entire group, and
26% of them had a normal neurological examination. The yield of CT scan
in patients with headaches and a normal neurological examination was
22.5% (95% IC: 14%-33%); of which we encountered the following
pathologies: intracranial tumors (13), hydrocephalus (2), arachnoid cyst (l),
toxoplasmic abscess (1) and parenchymal hemorrhage (1). The clinical
characteristics of the headache on their own was insufficient to rule out the
possibility of an intracranial tumor. Neuroimaging studies should be
performed in all adult patients with non-vascular headache of recent onset, I and previously headache-free individual
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
Producción CientíficaRecent preclinical evidence has suggested that Ewing Sarcoma (ES) bearing
EWSR1-ETS fusions could be particularly sensitive to PARP inhibitors (PARPinh) in
combination with DNA damage repair (DDR) agents. Trabectedin is an antitumoral
agent that modulates EWSR1-FLI1 transcriptional functions, causing DNA damage.
Interestingly, PARP1 is also a transcriptional regulator of EWSR1-FLI1, and PARPinh
disrupts the DDR machinery. Thus, given the impact and apparent specificity of both
agents with regard to the DNA damage/DDR system and EWSR1-FLI1 activity in
ES, we decided to explore the activity of combining PARPinh and Trabectedin in in
vitro and in vivo experiments. The combination of Olaparib and Trabectedin was
found to be highly synergistic, inhibiting cell proliferation, inducing apoptosis, and
the accumulation of G2/M. The drug combination also enhanced γH2AX intranuclear
accumulation as a result of DNA damage induction, DNA fragmentation and global DDR
deregulation, while EWSR1-FLI1 target expression remained unaffected. The effect of
the drug combination was corroborated in a mouse xenograft model of ES and, more
importantly, in two ES patient-derived xenograft (PDX) models in which the tumors
showed complete regression. In conclusion, the combination of the two agents leads
to a biologically significant deregulation of the DDR machinery that elicits relevant
antitumor activity in preclinical models and might represent a promising therapeutic
tool that should be further explored for translation to the clinical setting.Ministerio de Economía y Competitividad (PI081828)Ministerio de Economía y Competitividad (RD06/0020/0059 )Ministerio de Economía y Competitividad (RD12/0036/0017)Ministerio de Economía y Competitividad (PT13/0010/0056
Multiancestry analysis of the HLA locus in Alzheimer’s and Parkinson’s diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes
Across multiancestry groups, we analyzed Human Leukocyte Antigen (HLA) associations in over 176,000 individuals with Parkinson’s disease (PD) and Alzheimer’s disease (AD) versus controls. We demonstrate that the two diseases share the same protective association at the HLA locus. HLA-specific fine-mapping showed that hierarchical protective effects of HLA-DRB1*04 subtypes best accounted for the association, strongest with HLA-DRB1*04:04 and HLA-DRB1*04:07, and intermediary with HLA-DRB1*04:01 and HLA-DRB1*04:03. The same signal was associated with decreased neurofibrillary tangles in postmortem brains and was associated with reduced tau levels in cerebrospinal fluid and to a lower extent with increased Aβ42. Protective HLA-DRB1*04 subtypes strongly bound the aggregation-prone tau PHF6 sequence, however only when acetylated at a lysine (K311), a common posttranslational modification central to tau aggregation. An HLA-DRB1*04-mediated adaptive immune response decreases PD and AD risks, potentially by acting against tau, offering the possibility of therapeutic avenues
Psicocirugía. Pasado y presente. A propósito de un caso, en relación con la hermana de J.F. Kennedy.
From the search inside the complex biography of the case of a patient, as well as finding similarities with other operations such as the psychosurgery made to Rosemary Kennedy, we get into a journey that lead us from the early beginning to the present psychosurgery, from its origins, successes and failures as well as their current status. Neuroanatomical features including biosocial psychopathological are considered. A journey to the future from the beginnings of psychosurgery, with its lights and shadows, until now. At the end we will discover how much psychiatry has been developed during the last 30 years, and how this pioneers discovered a way of treatment that is still being used in some specific indications, like severe OCD.Apresentamos o caso de uma paciente com dano cognitivo moderado que foi submetida a psicocirurgia. A busca na complexa biografia da paciente, assim como o paralelismo temporal com outras operações de psicocirurgia (como a de Rosemary Kennedy), conduzem a aprofundar a respeito do passado desta técnica, suas origens, erros e acertos, assim como seu estado atual. Se consideram tanto os elementos neuroanatômicos, como psicopatológicos e biossociais. Tudo isso nos leva a uma viagem ao passado desde os inícios da psicocirurgia; com suas luzes e suas sombras, até o momento atual.Presentamos el caso de una paciente con deterioro cognitivo moderado que fue sometida a psicocirugía. La búsqueda en la compleja biografía de la paciente, así como el paralelismo temporal con otras operaciones de psicocirugía (como la de Rosemary Kennedy), conducen a profundizar respecto al pasado de esta técnica, sus orígenes, errores y aciertos, así como su estado actual. Se consideran tanto los elementos neuroanatómicos, como psicopatológicos y biosociales. Todo ello nos conduce a un viaje al pasado desde los inicios de la psicocirugía; con sus luces y sus sombras, hasta el momento actual
Evolución inmediata y a medio plazo de las dehiscencias paravalvulares cerradas percutáneamente
IgA Nephropathy in Elderly Patients.
Some studies suggest that the incidence of IgA nephropathy is increasing in older adults, but there is a lack of information about the epidemiology and behavior of the disease in that age group. In this retrospective multicentric study, we analyzed the incidence, forms of presentation, clinical and histologic characteristics, treatments received, and outcomes in a cohort of 151 patients ≥65 years old with biopsy-proven IgA nephropathy diagnosed between 1990 and 2015. The main outcome was a composite end point of kidney replacement therapy or death before kidney replacement therapy. We found a significant increase in the diagnosis of IgA nephropathy over time from six patients in 1990-1995 to 62 in 2011-2015 (P value for trend =0.03). After asymptomatic urinary abnormalities (84 patients; 55%), AKI was the most common form of presentation (61 patients; 40%). Within the latter, 53 (86%) patients presented with hematuria-related AKI (gross hematuria and tubular necrosis associated with erythrocyte casts as the most important lesions in kidney biopsy), and eight patients presented with crescentic IgA nephropathy. Six (4%) patients presented with nephrotic syndrome. Among hematuria-related AKI, 18 (34%) patients were receiving oral anticoagulants, and this proportion rose to 42% among the 34 patients older than 72 years old who presented with hematuria-related AKI. For the whole cohort, survival rates without the composite end point were 74%, 48%, and 26% at 1, 2, and 5 years, respectively. Age, serum creatinine at presentation, and the degree of interstitial fibrosis in kidney biopsy were risk factors significantly associated with the outcome, whereas treatment with renin-angiotensin-aldosterone blockers was associated with a lower risk. Immunosuppressive treatments were not significantly associated with the outcome. The diagnosis of IgA nephropathy among older adults in Spain has progressively increased in recent years, and anticoagulant therapy may be partially responsible for this trend. Prognosis was poor. This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_07_16_CJASNPodcast_19_08_.mp3
IgA Nephropathy in Elderly Patients
Some studies suggest that the incidence of IgA nephropathy is increasing in older adults, but there is a lack of information about the epidemiology and behavior of the disease in that age group. In this retrospective multicentric study, we analyzed the incidence, forms of presentation, clinical and histologic characteristics, treatments received, and outcomes in a cohort of 151 patients ≥65 years old with biopsy-proven IgA nephropathy diagnosed between 1990 and 2015. The main outcome was a composite end point of kidney replacement therapy or death before kidney replacement therapy. We found a significant increase in the diagnosis of IgA nephropathy over time from six patients in 1990-1995 to 62 in 2011-2015 (P value for trend =0.03). After asymptomatic urinary abnormalities (84 patients; 55%), AKI was the most common form of presentation (61 patients; 40%). Within the latter, 53 (86%) patients presented with hematuria-related AKI (gross hematuria and tubular necrosis associated with erythrocyte casts as the most important lesions in kidney biopsy), and eight patients presented with crescentic IgA nephropathy. Six (4%) patients presented with nephrotic syndrome. Among hematuria-related AKI, 18 (34%) patients were receiving oral anticoagulants, and this proportion rose to 42% among the 34 patients older than 72 years old who presented with hematuria-related AKI. For the whole cohort, survival rates without the composite end point were 74%, 48%, and 26% at 1, 2, and 5 years, respectively. Age, serum creatinine at presentation, and the degree of interstitial fibrosis in kidney biopsy were risk factors significantly associated with the outcome, whereas treatment with renin-angiotensin-aldosterone blockers was associated with a lower risk. Immunosuppressive treatments were not significantly associated with the outcome. The diagnosis of IgA nephropathy among older adults in Spain has progressively increased in recent years, and anticoagulant therapy may be partially responsible for this trend. Prognosis was poor. This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_07_16_CJASNPodcast_19_08_.mp3
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Most patients with colorectal cancer die as a result of the disease spreading to other organs. However, no prevalent mutations have been associated with metastatic colorectal cancers1,2. Instead, particular features of the tumour microenvironment, such as lack of T-cell infiltration3, low type 1 T-helper cell (TH1) activity and reduced immune cytotoxicity2 or increased TGFβ levels4 predict adverse outcomes in patients with colorectal cancer. Here we analyse the interplay between genetic alterations and the tumour microenvironment by crossing mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. Quadruple-mutant mice developed metastatic intestinal tumours that display key hallmarks of human microsatellite-stable colorectal cancers, including low mutational burden5, T-cell exclusion3 and TGFβ-activated stroma4,6,7. Inhibition of the PD-1–PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGFβ unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1–PD-L1 therapy. Our data show that increased TGFβ in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the TH1-effector phenotype. Immunotherapies directed against TGFβ signalling may therefore have broad applications in treating patients with advanced colorectal cancer